Objectives: Establishing the clinical pathological characteristics of adenocarcinomata of the esophagogastric junction of an insured population in our environment.

Material And Methods: In this retrospective study, we studied sixty clinical histories of patients with a diagnosis of gastric adenocarcinomata, who had been surgically treated at the Edgardo Rebagliati Martins Hospital, 3C II Department of Surgery, EESALUD , Lima, Peru, from September 2002 to December 2004, and cases located at the esophagogastric junction (EGJ) were selected. Data were collected regarding: age, gender, presentation symptoms, anatomic location of the tumor, regional lymphatic metastasis (N), distance metastasis (M), TNM staging, excisability, complications, mortality and histological type.

Results: Distribution according to anatomic location: 50% (30/60) were located at the esophagogastric junction, 23% (14/60) in the body and 27% (16/60) in the antrum. Of the 30 patients with adenocarcinomata of the EGJ, 80% (24/30) were male, 60% (18/30) were in their 60's or 70's and 47% (14/30) had upper gastrointestinal hemorrhage (UGIH). Type III tumors (subcardial) of the EGJ were found in 76% (23/30), in 63% (12/19) of the excised patients the serosa was affected, in 74% (14/19) the ganglia were affected and 83% (25/30) fell into stages III through IV. Excisions were performed on 63% (19/30), 42% (8/19) experienced complications, mortality was 10.5% (2/19) and in 67% (20/30) the histological type was clearly differentiated.

Conclusions: At our Hospital there seems to be an increase in the frequency of adenocarcinomata of the esophagogastric junction at the expense of other locations. Also, the subcardial type is more frequent than the cardial and distal esophagus types.

Download full-text PDF

Source

Publication Analysis

Top Keywords

esophagogastric junction
20
edgardo rebagliati
8
adenocarcinomata esophagogastric
8
located esophagogastric
8
anatomic location
8
complications mortality
8
junction
5
[cancer esophagogastric
4
junction edgardo
4
rebagliati martíns
4

Similar Publications

Whether preoperative chemoradiotherapy (CRT) or perioperative chemotherapy is superior for localized esophageal or gastro-esophageal junction (GEJ) cancers has been a topic of long-standing debate. For years, standard of care in the United States for localized esophageal or GEJ adenocarcinoma (EAC) has been physician's choice between the 2 strategies. More recently, adjuvant immunotherapy has also been introduced into the treatment approach for those who received neoadjuvant CRT.

View Article and Find Full Text PDF

Background: Macranthoside B (MB) is a saponin compound extracted from hon-eysuckle that has been reported to exhibit significant medicinal values, particularly anti-tumor activities. This study aimed to evaluate the anticancer efficacy of MB in treating adenocarci-noma of the esophagogastric junction (AEG) and elucidate its underlying mechanisms.

Methods: Three AEG cell lines and normal gastric epithelial cells were used to assess the an-ticancer activity of MB in vitro.

View Article and Find Full Text PDF

No consensus exists on the optimal therapy for resectable gastric cancer (GC) and gastroesophageal junction (GEJ) tumors, including the effectiveness of chemoradiotherapy versus perioperative chemotherapy (PC). Our study aimed to compare overall survival (OS) outcomes associated with the recommended treatment modalities for GC and GEJ tumors and evaluate treatment trends from 2010 to 2020. A national registry cohort identified patients with ≥ cT2 nonmetastatic GC and GEJ cancer.

View Article and Find Full Text PDF

Background And Aim: Laparoscopic Nissen fundoplication (LNF) is the gold standard of antireflux surgery. Up to 30% of patients experience symptoms after surgery, with insufficient information available. The main objective is to evaluate epidemiological, clinical, and functional factors associated with symptoms after LNP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!